Skinvisible, Inc.
29.5.2024 12:32:39 CEST | ACCESS Newswire | Press release
Administration of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Enhanced by Invisicare Topical / Transdermal Delivery System
LAS VEGAS, NV / ACCESSWIRE / May 29, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity. The Company has achieved a significant milestone by officially filing a provisional patent application covering formulations that leverage the Company's proprietary delivery technology Invisicare® for the transdermal administration of obesity drugs. Titled "Transdermal Delivery Composition for Delivery of CB-1 Receptor Antagonists and/or GLP-1 Receptor Agonists, and Method of Delivery," this patent filing ushers in a new era of efficient and convenient obesity drug delivery solutions.
The patent application focuses on Invisicare; a patented transdermal delivery technology designed to incorporate CB-1 receptor antagonists and/or GPL-1 receptor agonists, two classes of drugs known for their potential in obesity management, into a lotion that is applied topically to the skin using a metered applicator. Studies have demonstrated the superior transdermal penetration and controlled release of other active compounds using Invisicare's innovative technology; with certain actives exhibiting up to a tenfold increase in transdermal delivery effectiveness. By utilizing Invisicare, Skinvisible aims to not only offer patients a convenient and effective alternative to traditional oral or injectable therapies but to also enhance drug efficacy and potentially significantly reduce side effects as transdermal delivery avoids first-pass metabolism. Additionally, for long-term treatment of obesity, a transdermal delivery system could feasibly provide a convenient method for administering maintenance doses of anti-obesity medications.
The global obesity drug market is poised to exceed $30 billion by 2027, propelled by the escalating prevalence of obesity worldwide and the eagerly anticipated advent of revolutionary anti-obesity medications. Nonetheless, the impediment posed by needles and injections remains a formidable barrier to access and compliance. Skinvisible's proprietary transdermal delivery technology overcomes this obstacle, unlocking the full therapeutic potential of CB-1 and GLP-1 targeting drugs.
"Our transdermal technology has the potential to revolutionize how obesity drugs are administered, granting patients access to potent weight loss medications through the ease and convenience of a metered dose of lotion simply applied to the skin," remarked Terry Howlett, CEO of Skinvisible Pharmaceuticals. "This needle-free approach holds immense promise in enhancing treatment adherence and broadening the accessibility of obesity therapies to countless individuals grappling with weight-related challenges." He added, "This groundbreaking patent application highlights our proficiency in transdermal delivery and underscores our commitment to leveraging this capability to reshape treatment standards."
Skinvisible is actively pursuing strategic partnerships with pharmaceutical and/or biotech companies to facilitate the introduction of the first transdermal obesity therapies to market and to explore the application of its delivery platform across diverse disease domains.
For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2024).
###
Contacts:
Strategic Partnerships: Doreen McMorran - doreen@invisicare.com
Corporate Inquiries: info@skinvisible.com Office Number: 702-433-7154 (PST)
SOURCE: Skinvisible, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination1.8.2026 01:15:00 CEST | Press release
Strategic Transaction to Position Thunder Bay North for Development, Strengthen Capital Markets Profile and Create a New Critical Minerals Growth Platform Not for distribution to United States newswire services or for dissemination in the United States. Highlights A strategic business combination with Springbok Ventures, a Fiore Group-backed company focused on critical minerals in Ontario Creation of a growth-oriented critical minerals platform focused on domestic critical minerals in Canada with the ability to pursue future acquisitions and strategic opportunities Minimum C$5 million concurrent financing of subscription receipts Partnership with the Fiore Group, one of Canada's leading mining groups Continued advancement of the Thunder Bay North Critical Minerals Project Addition of the Maude Lake Property in Ontario as an exploration asset THUNDER BAY, ON / ACCESS Newswire / July 31, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF), 1602037 B.C. Ltd.
Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested30.7.2026 21:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 30, 2026 / A new scientific review has found that nutritionally sound vegan dog food, vegan cat food and vegetarian pet diets are generally well digested and broadly comparable to conventional meat-based diets. The review, published in the journal Animals, examined 31 existing studies assessing the digestibility of vegan, vegetarian and plant-based pet diets and ingredients in dogs and cats. Twenty-two studies focused on dogs, two on cats and seven included both species. The review found that across a wide range of study designs, dietary ingredients and digestibility measures, vegan and vegetarian diets consistently showed high digestibility and were not normally significantly less digestible than conventional meat-based diets. Digestibility is an important factor because it indicates how effectively animals can absorb and utilise nutrients from food. While modern commercial plant-based pet foods are generally formulated to provide all essential nutr
Polaris Renewable Energy Announces Q2 2026 Results30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS Second quarter consolidated energy production totaled 199,130 MWh, representing a 8% decrease from 215,797 MWh in the same quarter last year. The decrease was consistent with management's expectations and primarily reflects higher curtailment in the Dominican Republic and the return to normalized hydrological conditions in Peru and Ecuador. The comparative period benefited from exceptionally strong
Polaris Renewable Energy Declares Quarterly Dividend30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on August 21st, 2026, to shareholders of record at the close of business on August 10th, 2026. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compa
New GTDC Research Illuminates Distribution's Expanding Role in Modern Technology Ecosystems29.7.2026 15:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / July 29, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, today released a new research report, The Evolving Role of Distribution in Technology Go-To-Market Models, developed in partnership with Channelnomics. The study examines the shift in distribution from a traditional channel intermediary into a strategic operating platform that helps vendors and partners scale, increase support and overcome the complexities associated with innovation (i.e., AI and cybersecurity) and integration. According to the research, customer expectations are rising rapidly as organizations seek integrated outcomes across AI, cybersecurity, hybrid cloud, automation, analytics and managed services. Vendors and partners increasingly struggle to meet those market demands independently with solutions requiring cross-platform integration, multi-vendor coordination, lifecycle support and operational consistency. The G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom